المؤلفون: Ascierto, Paolo A., Bastholt, Lars, Ferrucci, Pier F., Hansson, Johan, Márquez Rodas, Iván, Payne, Miranda, Robert, Caroline, Thomas, Luc, Utikal, Jochen S., Wolter, Pascal, Kudlac, Amber, Tuson, Harriet, McKendrick, Jan

المصدر: Ascierto , P A , Bastholt , L , Ferrucci , P F , Hansson , J , Márquez Rodas , I , Payne , M , Robert , C , Thomas , L , Utikal , J S , Wolter , P , Kudlac , A , Tuson , H & McKendrick , J 2018 , ' The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma : Results from a European expert panel study ' , Melanoma Research , vol. 28 , no. 4 , pp. 333-340 . https://doi.org/10.1097/CMR.0000000000000455Test

مصطلحات موضوعية: advanced melanoma, BRAF/MEK inhibitors, checkpoint inhibitors, expert opinion, factors, first-line treatment decision, immunotherapy, selecting therapy

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/425684a0-58df-411c-a0c7-dcc0879c907fTest

الإتاحة: https://doi.org/10.1097/CMR.0000000000000455Test
https://portal.findresearcher.sdu.dk/da/publications/425684a0-58df-411c-a0c7-dcc0879c907fTest
https://findresearcher.sdu.dk/ws/files/143487374/The_impact_of_patient_characteristics_and_disease_specific_factors_on_first_line_treatment_decisions_for_BRAF_mutated_melanoma.pdfTest

المؤلفون: Lars Bastholt, Ivan Marquez Rodas, Jochen Utikal, Pier Francesco Ferrucci, Harriet Tuson, Luc Thomas, Miranda Payne, Pascal Wolter, Caroline Robert, J McKendrick, Johan Hansson, Paolo A. Ascierto, Amber Kudlac

المصدر: Melanoma Research
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ascierto, P A, Bastholt, L, Ferrucci, P F, Hansson, J, Márquez Rodas, I, Payne, M, Robert, C, Thomas, L, Utikal, J S, Wolter, P, Kudlac, A, Tuson, H & McKendrick, J 2018, ' The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma : Results from a European expert panel study ', Melanoma Research, vol. 28, no. 4, pp. 333-340 . https://doi.org/10.1097/CMR.0000000000000455Test

مصطلحات موضوعية: Disease specific, Male, Proto-Oncogene Proteins B-raf, advanced melanoma, Cancer Research, medicine.medical_specialty, Skin Neoplasms, BRAF/MEK inhibitors, medicine.medical_treatment, Delphi method, Patient characteristics, Dermatology, Targeted therapy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Surveys and Questionnaires, medicine, Humans, Intensive care medicine, Melanoma, Advanced melanoma, business.industry, factors, selecting therapy, medicine.disease, ORIGINAL ARTICLES: Clinical research, expert opinion, First line treatment, Europe, Oncology, first-line treatment decision, 030220 oncology & carcinogenesis, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, Treatment decision making, immunotherapy, business, checkpoint inhibitors

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee4e9e62e780a228a3f3cccf6e9e120Test
https://pubmed.ncbi.nlm.nih.gov/29750751Test